We allocate around 18% of our revenue to research and development to provide environmentally sound, safe and efficacious products for the aquaculture industry.
We stay in the forefront of our business through significant investments in research and development to meet new disease challenges facing the global fish farming industry. Currently, we are doing extensive research on the next generation of sea lice products to reduce this threat to the industry. At the same time we are investing extensively in new vaccine products for salmon, trout, pangasius and seabass among other aquaculture species. We are also exploring new technologies to improve fish health.
We have a dynamic project portfolio management and enthusiastic projects leaders.
As we are preparing to move into new aquaculture markets to cover new species, we have decided to expand the company. An expansion which will not only benefit PHARMAQ, but also our customers, the industry and the environment.
A new disease challenge or a market often leads to establishment of a qualified project group. Behind a new product several years of research, development and documentation is needed to ensure high quality products that give the needed level of and duration of protection, as well as safe and healthy fish.
In order to achieve freedom to operate, PHARMAQ actively utilises IPR to create value and competitive advantages. Several patents and patent applications covering future products and technologies are held by the company.